-
1
-
-
19944390213
-
Pathogenesis of type 2 diabetes mellitus
-
Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res 2005; 36: 197-209.
-
(2005)
Arch Med Res
, vol.36
, pp. 197-209
-
-
Leahy, J.L.1
-
2
-
-
0035431520
-
Importance of postprandial glucose control
-
Bell DS. Importance of postprandial glucose control. South Med J 2001; 94: 804-809.
-
(2001)
South Med J
, vol.94
, pp. 804-809
-
-
Bell, D.S.1
-
3
-
-
0023916553
-
Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus
-
Polonsky KS, Given BD, Hirsch LJ et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 1231-1239.
-
(1988)
N Engl J Med
, vol.318
, pp. 1231-1239
-
-
Polonsky, K.S.1
Given, B.D.2
Hirsch, L.J.3
-
4
-
-
0030596338
-
Non-insulin dependent diabetes mellitus - A genetically programmed failure of the beta cell to compensate for insulin resistance
-
Polonsky KS, Sturis J, Bell GI. Non-insulin dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996; 334: 777-783.
-
(1996)
N Engl J Med
, vol.334
, pp. 777-783
-
-
Polonsky, K.S.1
Sturis, J.2
Bell, G.I.3
-
5
-
-
0028606422
-
A glimpse of the 'natural history' of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis
-
Coates PA, Ollerton RL, Luzio SD, Ismail I, Owens DR. A glimpse of the 'natural history' of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. Diabetes Res Clin Pract 1994; 26: 177-187.
-
(1994)
Diabetes Res Clin Pract
, vol.26
, pp. 177-187
-
-
Coates, P.A.1
Ollerton, R.L.2
Luzio, S.D.3
Ismail, I.4
Owens, D.R.5
-
6
-
-
0032613269
-
Rapid-acting insulin secretagogues: A clinical need?
-
Home PD. Rapid-acting insulin secretagogues: A clinical need? Exp Clin Endocrinol Diabetes 1999; 107(Suppl. 4): S115-119.
-
(1999)
Exp Clin Endocrinol Diabetes
, vol.107
, Issue.SUPPL. 4
-
-
Home, P.D.1
-
7
-
-
0037737732
-
Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review
-
DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 2003; 289: 2254-2264.
-
(2003)
JAMA
, vol.289
, pp. 2254-2264
-
-
DeWitt, D.E.1
Hirsch, I.B.2
-
8
-
-
0005169502
-
United Kingdom Prospective Diabetes Study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy
-
UK Prospective Diabetes Study (UKPDS) Group
-
UK Prospective Diabetes Study (UKPDS) Group. United Kingdom Prospective Diabetes Study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998; 128: 165-175.
-
(1998)
Ann Intern Med
, vol.128
, pp. 165-175
-
-
-
9
-
-
0031912676
-
High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study
-
Balkau B, Shipley M, Jarrett RJ et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360-367.
-
(1998)
Diabetes Care
, vol.21
, pp. 360-367
-
-
Balkau, B.1
Shipley, M.2
Jarrett, R.J.3
-
10
-
-
0033592101
-
Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria
-
DECODE study group, on behalf of the European Diabetes Epidemiology Group
-
DECODE study group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-621.
-
(1999)
Lancet
, vol.354
, pp. 617-621
-
-
-
11
-
-
0035847591
-
Glucose tolerance and cardiovascular mortality
-
DECODE study group, on behalf of the European Diabetes Epidemiology Group
-
DECODE study group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality. Arch Intern Med 2001; 161: 397-404.
-
(2001)
Arch Intern Med
, vol.161
, pp. 397-404
-
-
-
12
-
-
0034641568
-
Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
-
Stratton IM, Adler AI, Neil HA et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-412.
-
(2000)
BMJ
, vol.321
, pp. 405-412
-
-
Stratton, I.M.1
Adler, A.I.2
Neil, H.A.3
-
13
-
-
0032511583
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
-
UK Prospective Diabetes Study (UKPDS) Group
-
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
-
(1998)
Lancet
, vol.352
, pp. 837-853
-
-
-
14
-
-
0042166232
-
Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c)
-
Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885.
-
(2003)
Diabetes Care
, vol.26
, pp. 881-885
-
-
Monnier, L.1
Lapinski, H.2
Colette, C.3
-
15
-
-
0003191727
-
Medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management-2002 update
-
American Association of Clinical Endocrinologists
-
American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management-2002 update. Endocr Pract 2002; 8(Suppl. 1): 40-82.
-
(2002)
Endocr Pract
, vol.8
, Issue.SUPPL. 1
, pp. 40-82
-
-
-
16
-
-
0032887833
-
A desktop guide to type 2 diabetes mellitus
-
International Diabetes Federation (European Diabetes Policy Group)
-
International Diabetes Federation (European Diabetes Policy Group). A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-730.
-
(1999)
Diabet Med
, vol.16
, pp. 716-730
-
-
-
17
-
-
13044287359
-
Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: The possible role of hyperglycemia
-
Ceriello A, Bortolotti N, Motz E et al. Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: The possible role of hyperglycemia. Metabolism 1999; 48: 1503-1508.
-
(1999)
Metabolism
, vol.48
, pp. 1503-1508
-
-
Ceriello, A.1
Bortolotti, N.2
Motz, E.3
-
18
-
-
1242292299
-
The post-prandial state in type 2 diabetes and endothelial dysfunction: Effects of insulin aspart
-
Ceriello A, Cavarape A, Martinelli L et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: Effects of insulin aspart. Diabet Med 2004; 21: 171-175.
-
(2004)
Diabet Med
, vol.21
, pp. 171-175
-
-
Ceriello, A.1
Cavarape, A.2
Martinelli, L.3
-
19
-
-
0042093769
-
New insights on oxidative stress and diabetic complications may lead to a 'causal' antioxidant therapy
-
Ceriello A. New insights on oxidative stress and diabetic complications may lead to a 'causal' antioxidant therapy. Diabetes Care 2003; 26: 1589-1596.
-
(2003)
Diabetes Care
, vol.26
, pp. 1589-1596
-
-
Ceriello, A.1
-
20
-
-
0029957413
-
Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up
-
Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-1583.
-
(1996)
Diabetologia
, vol.39
, pp. 1577-1583
-
-
Hanefeld, M.1
Fischer, S.2
Julius, U.3
-
21
-
-
0032983666
-
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group
-
Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 20005-20012.
-
(1999)
JAMA
, vol.281
, pp. 20005-20012
-
-
Turner, R.C.1
Cull, C.A.2
Frighi, V.3
Holman, R.R.4
-
22
-
-
0036701596
-
Novel insulins: Expanding options in diabetes management
-
Gerich JE. Novel insulins: Expanding options in diabetes management. Am J Med 2002; 113: 308-316.
-
(2002)
Am J Med
, vol.113
, pp. 308-316
-
-
Gerich, J.E.1
-
23
-
-
17844377294
-
Intensifying insulin therapy in patients with type 2 diabetes mellitus
-
Hirsch IB. Intensifying insulin therapy in patients with type 2 diabetes mellitus. Am J Med 2005; 118 (Suppl. 5A): 21S-26S.
-
(2005)
Am J Med
, vol.118
, Issue.SUPPL. 5A
-
-
Hirsch, I.B.1
-
24
-
-
8644242919
-
Overcoming obstacles: New management options
-
Heinemann L. Overcoming obstacles: New management options. Eur J Endocrinol 2004; 151 (Suppl. 2): T23-T27.
-
(2004)
Eur J Endocrinol
, vol.151
, Issue.SUPPL. 2
-
-
Heinemann, L.1
-
25
-
-
17844406362
-
Making the transition from oral to insulin therapy
-
Riddle MC. Making the transition from oral to insulin therapy. Am J Med 2005; 118 (Suppl. 5A): 14S-20S.
-
(2005)
Am J Med
, vol.118
, Issue.SUPPL. 5A
-
-
Riddle, M.C.1
-
26
-
-
0025078913
-
Monomeric insulins and their experimental and clinical implications
-
Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13: 923-954.
-
(1990)
Diabetes Care
, vol.13
, pp. 923-954
-
-
Brange, J.1
Owens, D.R.2
Kang, S.3
Volund, A.4
-
28
-
-
0030805003
-
The new era of biotech insulin analogs
-
Brange J. The new era of biotech insulin analogs. Diabetologia 1997; 40(Suppl. 2): S48-S53.
-
(1997)
Diabetologia
, vol.40
, Issue.SUPPL. 2
-
-
Brange, J.1
-
29
-
-
0342657181
-
Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use
-
Kurtzhals P, Schaffer L, Sorensen A et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.
-
(2000)
Diabetes
, vol.49
, pp. 999-1005
-
-
Kurtzhals, P.1
Schaffer, L.2
Sorensen, A.3
-
31
-
-
0032969538
-
Insulin analogs with improved pharmacokinetic profiles
-
Brange J, Volund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 1999; 35: 307-335.
-
(1999)
Adv Drug Deliv Rev
, vol.35
, pp. 307-335
-
-
Brange, J.1
Volund, A.2
-
32
-
-
0034968761
-
Physiological insulin replacement in type 1 diabetes mellitus
-
Bolli GB. Physiological insulin replacement in type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 2001; 109(Suppl. 2): S317-332.
-
(2001)
Exp Clin Endocrinol Diabetes
, vol.109
, Issue.SUPPL. 2
-
-
Bolli, G.B.1
-
33
-
-
0033060426
-
Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analog, insulin aspart, in healthy volunteers
-
Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analog, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 1999; 55: 199-203.
-
(1999)
Eur J Clin Pharmacol
, vol.55
, pp. 199-203
-
-
Home, P.D.1
Barriocanal, L.2
Lindholm, A.3
-
34
-
-
0032841674
-
Insulin aspart (B28 asp-insulin): A fast-acting analog of human insulin: Absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects
-
Mudaliar SR, Lindberg FA, Joyce M et al. Insulin aspart (B28 asp-insulin): A fast-acting analoA of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999; 22: 1501-1506.
-
(1999)
Diabetes Care
, vol.22
, pp. 1501-1506
-
-
Mudaliar, S.R.1
Lindberg, F.A.2
Joyce, M.3
-
35
-
-
0030876297
-
Insulin lispro: A new quick-acting insulin analog
-
Gale EA. Insulin lispro: A new quick-acting insulin analog. Expert Opin Investig Drugs 1997; 6: 1247-1256.
-
(1997)
Expert Opin Investig Drugs
, vol.6
, pp. 1247-1256
-
-
Gale, E.A.1
-
36
-
-
1542787613
-
Comparison of insulin aspart and lispro: Pharmacokinetic and metabolic effects
-
Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G. Comparison of insulin aspart and lispro: Pharmacokinetic and metabolic effects. Diabetes Care 2003; 26: 2027-2031.
-
(2003)
Diabetes Care
, vol.26
, pp. 2027-2031
-
-
Homko, C.1
Deluzio, A.2
Jimenez, C.3
Kolaczynski, J.W.4
Boden, G.5
-
37
-
-
0036833902
-
A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes
-
Plank J, Wutte A, Brunner G et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002; 25: 2053-2057.
-
(2002)
Diabetes Care
, vol.25
, pp. 2053-2057
-
-
Plank, J.1
Wutte, A.2
Brunner, G.3
-
38
-
-
0030867217
-
Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture
-
Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997; 20: 1612-1614.
-
(1997)
Diabetes Care
, vol.20
, pp. 1612-1614
-
-
Weyer, C.1
Heise, T.2
Heinemann, L.3
-
39
-
-
0033848386
-
Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart
-
Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000; 56: 399-403.
-
(2000)
Eur J Clin Pharmacol
, vol.56
, pp. 399-403
-
-
Jacobsen, L.V.1
Sogaard, B.2
Riis, A.3
-
40
-
-
0036581025
-
Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes
-
Hermansen K, Colombo M, Storgaard H et al. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002; 25: 883-888.
-
(2002)
Diabetes Care
, vol.25
, pp. 883-888
-
-
Hermansen, K.1
Colombo, M.2
Storgaard, H.3
-
41
-
-
0036250511
-
Twice-daily biphasic insulin aspart 30 vs biphasic human insulin 30: A double-blind crossover study in adults with type 2 diabetes mellitus
-
McSorley P, Bell P, Jacobsen L et al. Twice-daily biphasic insulin aspart 30 vs biphasic human insulin 30: A double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002; 24: 530-539.
-
(2002)
Clin Ther
, vol.24
, pp. 530-539
-
-
McSorley, P.1
Bell, P.2
Jacobsen, L.3
-
42
-
-
0029045224
-
Do insulin-treated diabetic patients use an injection-meal-interval in daily life?
-
Heinemann L. Do insulin-treated diabetic patients use an injection-meal-interval in daily life? Diabet Med 1995; 12: 449-450.
-
(1995)
Diabet Med
, vol.12
, pp. 449-450
-
-
Heinemann, L.1
-
43
-
-
0032918159
-
Injection-meal interval: Recommendations of diabetologists and how patients handle it
-
Overmann H, Heinemann L. Injection-meal interval: Recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract 1999; 43: 137-142.
-
(1999)
Diabetes Res Clin Pract
, vol.43
, pp. 137-142
-
-
Overmann, H.1
Heinemann, L.2
-
44
-
-
0027008265
-
Timing between the subcutaneous administration of insulin and consumption of a carbohydrate rich meal
-
Heinemann L, Starke AA, Hohmann A, Berger M. Timing between the subcutaneous administration of insulin and consumption of a carbohydrate rich meal. Horm Metab Res Suppl 1992; 26: 137-139.
-
(1992)
Horm Metab Res Suppl
, vol.26
, pp. 137-139
-
-
Heinemann, L.1
Starke, A.A.2
Hohmann, A.3
Berger, M.4
-
45
-
-
10744233670
-
Importance of premeal injection time in insulin therapy: Humalog Mix 75/ 25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits
-
Coscelli C, Iacobellis G, Calderini C et al. Importance of premeal injection time in insulin therapy: Humalog Mix 75/25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits. Acta Diabetol 2003; 40: 187-192.
-
(2003)
Acta Diabetol
, vol.40
, pp. 187-192
-
-
Coscelli, C.1
Iacobellis, G.2
Calderini, C.3
-
46
-
-
2342652848
-
Reduced postprandial glycemic excursion with biphasic insulin Aspart 30 injected immediately before a meal
-
Kapitza C, Rave K, Ostrowski K, Heise T, Heinemann L. Reduced postprandial glycemic excursion with biphasic insulin Aspart 30 injected immediately before a meal. Diabet Med 2004; 21: 500-501.
-
(2004)
Diabet Med
, vol.21
, pp. 500-501
-
-
Kapitza, C.1
Rave, K.2
Ostrowski, K.3
Heise, T.4
Heinemann, L.5
-
47
-
-
4444380085
-
Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients
-
Warren ML, Conway MJ, Klaff LJ, Rosenstock J, Allen E. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients. Diabetes Res Clin Pract 2004; 66: 23-29.
-
(2004)
Diabetes Res Clin Pract
, vol.66
, pp. 23-29
-
-
Warren, M.L.1
Conway, M.J.2
Klaff, L.J.3
Rosenstock, J.4
Allen, E.5
-
48
-
-
4243900460
-
Treatment with premixed insulin aspart 30 in type 1 and type 2 diabetes: A randomized 12-week comparison
-
Home PD, Boehm BO, Bott U, Behrend C, Kamp NM, Lindholm A. Treatment with premixed insulin aspart 30 in type 1 and type 2 diabetes: A randomized 12-week comparison. Diabetes Res Clin Pract 2000; 50 (Suppl. 1): S37.
-
(2000)
Diabetes Res Clin Pract
, vol.50
, Issue.SUPPL. 1
-
-
Home, P.D.1
Boehm, B.O.2
Bott, U.3
Behrend, C.4
Kamp, N.M.5
Lindholm, A.6
-
49
-
-
34249108029
-
Premixed 70/30 insulin aspart suspension improves insulin therapy related QoL in comparison with premixed 70/30 human insulin
-
Yamada S, Tamada T, Suzuki R, Yajima K, Motohashi Y, Shimada A. Premixed 70/30 insulin aspart suspension improves insulin therapy related QoL in comparison with premixed 70/30 human insulin. Diabetes 2005; 54(Suppl. 1): A119.
-
(2005)
Diabetes
, vol.54
, Issue.SUPPL. 1
-
-
Yamada, S.1
Tamada, T.2
Suzuki, R.3
Yajima, K.4
Motohashi, Y.5
Shimada, A.6
-
50
-
-
33746954143
-
Decreased rates of major hypoglycaemic events lead to improved long term cost effectiveness of biphasic insulin aspart 30/70 versus biphasic human insulin 30 in type 2 diabetic subjects in Danish, Finnish, German, Norwegian, Spanish, Swedish, and UK Settings
-
DB3
-
Lammert M, Palmer AJ, Roze S, Minshall ME, Valentine WJ. Decreased rates of major hypoglycaemic events lead to improved long term cost effectiveness of biphasic insulin aspart 30/70 versus biphasic human insulin 30 in type 2 diabetic subjects in Danish, Finnish, German, Norwegian, Spanish, Swedish, and UK Settings. Value Health 2004; 7: 649, DB3.
-
(2004)
Value Health
, vol.7
, pp. 649
-
-
Lammert, M.1
Palmer, A.J.2
Roze, S.3
Minshall, M.E.4
Valentine, W.J.5
-
51
-
-
0034104347
-
Improved postprandial glycemic control with Humalog Mix 75/25/25 after a standard test meal in patients with type 2 diabetes mellitus
-
Malone JK, Woodworth JR, Arora V et al. Improved postprandial glycemic control with Humalog Mix 75/25/25 after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther 2000; 22: 222-230.
-
(2000)
Clin Ther
, vol.22
, pp. 222-230
-
-
Malone, J.K.1
Woodworth, J.R.2
Arora, V.3
-
52
-
-
0037307367
-
A comparison of insulin lispro Mix 75/25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan
-
Mattoo V, Milicevic Z, Malone JK et al. A comparison of insulin lispro Mix 75/25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Res Clin Pract 2003; 59: 137-143.
-
(2003)
Diabetes Res Clin Pract
, vol.59
, pp. 137-143
-
-
Mattoo, V.1
Milicevic, Z.2
Malone, J.K.3
-
53
-
-
0032787906
-
Improved postprandial glycemic control during treatment with Humalog Mix 75/25, a novel protamine-based insulin lispro formulation
-
the Humalog Mix 75/25 Study Group
-
Roach P, Yue L, Arora V, the Humalog Mix 75/25 Study Group. Improved postprandial glycemic control during treatment with Humalog Mix 75/25, a novel protamine-based insulin lispro formulation. Diabetes Care 1999; 22: 1258-1261.
-
(1999)
Diabetes Care
, vol.22
, pp. 1258-1261
-
-
Roach, P.1
Yue, L.2
Arora, V.3
-
54
-
-
0036096925
-
Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: A randomized trial in type 1 and type 2 diabetic patients
-
Boehm B, Home P, Behrend C et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: A randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002; 19: 393-399.
-
(2002)
Diabet Med
, vol.19
, pp. 393-399
-
-
Boehm, B.1
Home, P.2
Behrend, C.3
-
55
-
-
0037368873
-
Humalog Mix 75/25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus
-
Herz M, Arora V, Campaigne BN, Scholtz HE, Potgieter MA, Mollentze W. Humalog Mix 75/25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus. S Afr Med J 2003; 93: 219-223.
-
(2003)
S Afr Med J
, vol.93
, pp. 219-223
-
-
Herz, M.1
Arora, V.2
Campaigne, B.N.3
Scholtz, H.E.4
Potgieter, M.A.5
Mollentze, W.6
-
56
-
-
25844515162
-
A randomized, multicentre trial of biphasic insulin aspart versus biphasic human insulin in type 2 diabetes
-
Iwamoto Y. A randomized, multicentre trial of biphasic insulin aspart versus biphasic human insulin in type 2 diabetes. Diabetologia 2003; 46 (Suppl. 2): A270.
-
(2003)
Diabetologia
, vol.46
, Issue.SUPPL. 2
-
-
Iwamoto, Y.1
-
57
-
-
14644421553
-
Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with type 1 diabetes: A randomized double-blinded crossover study
-
Chen J-W, Lauritzen T, Christiansen JJ, Jensen LH, Clausen WHO, Christiansen JS. Pharmacokinetic profiles of biphasic insulin aspart 30/ 70 and 70/30 in patients with type 1 diabetes: A randomized double-blinded crossover study. Diabet Med 2005; 22: 273-277.
-
(2005)
Diabet Med
, vol.22
, pp. 273-277
-
-
Chen, J.-W.1
Lauritzen, T.2
Christiansen, J.J.3
Jensen, L.H.4
Clausen, W.H.O.5
Christiansen, J.S.6
-
58
-
-
31344447303
-
Efficacy of biphasic insulin aspart 70/30 in patients with T2DM not achieving glycemic targets on OADs with/without basal insulin therapy
-
Jain R, Allen E, Wahl T et al. Efficacy of biphasic insulin aspart 70/30 in patients with T2DM not achieving glycemic targets on OADs with/ without basal insulin therapy. Diabetes 2005; 54(Suppl. 1): A69.
-
(2005)
Diabetes
, vol.54
, Issue.SUPPL. 1
-
-
Jain, R.1
Allen, E.2
Wahl, T.3
-
59
-
-
34547881925
-
Biphasic insulin aspart 30 (NovoLog Mix 70/30), a premier analog, is an effective and well tolerated starter insulin in type 2 diabetes
-
Ushakova O, Sokolovskaya V, Morozova A et al. Biphasic insulin aspart 30 (NovoLog Mix 70/30), a premier analog, is an effective and well tolerated starter insulin in type 2 diabetes. Diabetes 2005; 54 (Suppl. 1): A502.
-
(2005)
Diabetes
, vol.54
, Issue.SUPPL. 1
-
-
Ushakova, O.1
Sokolovskaya, V.2
Morozova, A.3
-
60
-
-
0034005755
-
The post-prandial state and cardiovascular disease: Relevance to diabetes mellitus
-
Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev 2000; 16: 125-132.
-
(2000)
Diabetes Metab Res Rev
, vol.16
, pp. 125-132
-
-
Ceriello, A.1
-
61
-
-
0024333622
-
Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study
-
Fontbonne A, Eschwege E, Cambien F et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32: 300-304.
-
(1989)
Diabetologia
, vol.32
, pp. 300-304
-
-
Fontbonne, A.1
Eschwege, E.2
Cambien, F.3
-
62
-
-
17144406856
-
Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with type 2 diabetes
-
Schmoelzer I, de Campo A, Pressl H et al. Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2005; 13: 176-181.
-
(2005)
Exp Clin Endocrinol Diabetes
, vol.13
, pp. 176-181
-
-
Schmoelzer, I.1
de Campo, A.2
Pressl, H.3
-
63
-
-
12844276715
-
Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes
-
Boehm BO, Vaz JA, Brønstedt L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med 2004; 15: 496-502.
-
(2004)
Eur J Intern Med
, vol.15
, pp. 496-502
-
-
Boehm, B.O.1
Vaz, J.A.2
Brønstedt, L.3
Home, P.D.4
-
64
-
-
25844443342
-
Patients with type 2 diabetes mellitus have lower rates of nocturnal hypoglycemia on biphasic insulin aspart (BIAsp 30) than on biphasic human insulin-30 (BHI30): Data from the REACH study
-
McNally P, Fitch M, Nelson G. Patients with type 2 diabetes mellitus have lower rates of nocturnal hypoglycemia on biphasic insulin aspart (BIAsp 30) than on biphasic human insulin-30 (BHI30): Data from the REACH study. Diabetologia 2004; 47(Suppl. 1): A327.
-
(2004)
Diabetologia
, vol.47
, Issue.SUPPL. 1
-
-
McNally, P.1
Fitch, M.2
Nelson, G.3
-
65
-
-
12844265257
-
Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs
-
Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-265.
-
(2005)
Diabetes Care
, vol.28
, pp. 260-265
-
-
Raskin, P.1
Allen, E.2
Hollander, P.3
-
66
-
-
18744383343
-
Can continuous glucose monitoring provide objective documentation of hypoglycemia unawareness?
-
Streja D. Can continuous glucose monitoring provide objective documentation of hypoglycemia unawareness? Endocr Pract 2005; 11: 83-90.
-
(2005)
Endocr Pract
, vol.11
, pp. 83-90
-
-
Streja, D.1
-
67
-
-
0036580827
-
Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes
-
Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Rastam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002; 25: 876-882.
-
(2002)
Diabetes Care
, vol.25
, pp. 876-882
-
-
Lindholm, A.1
Jensen, L.B.2
Home, P.D.3
Raskin, P.4
Boehm, B.O.5
Rastam, J.6
-
68
-
-
85073764666
-
Antibody formation, insulin dose and efficacy in a 4-year comparison of twice daily treatment with biphasic insulin aspart 30 or biphasic human insulin 30
-
Home P, Boehm BO, Raastam J, Keiding J. Antibody formation, insulin dose and efficacy in a 4-year comparison of twice daily treatment with biphasic insulin aspart 30 or biphasic human insulin 30. Diabetes 2004; 53(Suppl. 2): A310.
-
(2004)
Diabetes
, vol.53
, Issue.SUPPL. 2
-
-
Home, P.1
Boehm, B.O.2
Raastam, J.3
Keiding, J.4
|